Katherine A. Hutcheson

Katherine A. Hutcheson

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Katherine A. Hutcheson

University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2016 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
ECEzra E. W. Cohen
Ezra E. W. Cohen
SLSamuel J. LaMonte
Samuel J. LaMonte
NENicole L. Erb
Nicole L. Erb
KBKerry L. Beckman
Kerry L. Beckman
NSNader Sadeghi
Nader Sadeghi
Mandi L. Pratt-ChapmanMandi L. Pratt-Chapman
Mandi L. Pratt-Chapman

17 May 2012 in Cancer
Verified
Journal Article
Open access
PDF file
KHKatherine A. Hutcheson
Katherine A. Hutcheson
JLJan S. Lewin
Jan S. Lewin
DBDenise A. Barringer
Denise A. Barringer
ALAsher Lisec
Asher Lisec
GGG.BRandon Gunn
G.BRandon Gunn
FHF. Christopher Holsinger
F. Christopher Holsinger
BACKGROUND: Changing trends in head and neck cancer (HNC) merit an understanding of the late effects of therapy, but few studies examine dysphagia beyond 2 years of treatment.METHODS: A case series was examined to describe the pathophysiology and outcomes in dysphagic HNC survivors referred for modified barium swallow (MBS) studies ≥5 years after definitive radiotherapy or chemoradiotherapy (January 2001 through May 2011). Functional measures included the penetration‐aspiration scale (PAS), performance status scale–head and neck (PSS‐HN), National Institutes of Health Swallowing Safety Scale (NIH‐SSS), and MBS impairment profile (MBSImp).RESULTS: Twenty‐nine patients previously treated with radiotherapy (38%) or chemoradiotherapy (62%) were included (median years posttreatment, 9; range, 5‐19). The majority (86%) had oropharyngeal cancer; 52% were never‐smokers. Seventy‐five percent had T2 or T3 tumors; 52% were N+. The median age at diagnosis was 55 (range, 38‐72). Abnormal late examination findings included: dysarthria/dysphonia (76%), cranial neuropathy (48%), trismus (38%), and radionecrosis (10%). MBS studies confirmed pharyngeal residue and aspiration in all dysphagic cases owing to physiologic impairment (median PAS, 8; median NIH‐SSS, 10; median MBSImp, 18), whereas stricture was confirmed endoscopically in 7 (24%). Twenty‐five (86%) developed pneumonia, half requiring hospitalization. Swallow postures/strategies helped 69% of cases, but no patient achieved durable improvement across functional measures at last follow‐up. Ultimately, 19 (66%) were gastrostomy‐dependent.CONCLUSIONS: Although functional organ preservation is commonly achieved, severe dysphagia represents a challenging late effect that may develop or progress years after radiation‐based therapy for HNC. These data suggest that novel approaches are needed to minimize and better address this complication that is commonly refractory to many standard dysphagia therapies. Cancer 2012. © 2012 American Cancer Society.

1 September 2017 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Primož StrojanPrimož Strojan
Primož Strojan
KHKatherine A. Hutcheson
Katherine A. Hutcheson
AEAvraham Eisbruch
Avraham Eisbruch
JBJonathan J. Beitler
Jonathan J. Beitler
JLJohannes A. Langendijk
Johannes A. Langendijk
AFAlfio Ferlito
Alfio Ferlito

27 August 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WOWaheeda Owadally
Waheeda Owadally
CHChris Hurt
Chris Hurt
HTHayley Timmins
Hayley Timmins
EPEmma Parsons
Emma Parsons
STSarah Townsend
Sarah Townsend
MEMererid Evans
Mererid Evans
Human papillomavirus-positive oropharyngeal squamous cell carcinoma is increasing in incidence worldwide. Current treatments are associated with high survival rates but often result in significant long-term toxicities. In particular, long-term dysphagia has a negative impact on patient quality of life and health. The aim of PATHOS is to determine whether reducing the intensity of adjuvant treatment after minimally invasive transoral surgery in this favourable prognosis disease will result in better long-term swallowing function whilst maintaining excellent disease-specific survival outcomes. The study is a multicentre phase II/III randomised controlled trial for patients with biopsy-proven Human papillomavirus-positive oropharyngeal squamous cell cancer staged T1-T3 N0-N2b with a primary tumour that is resectable via a transoral approach. Following transoral surgery and neck dissection, patients are allocated into three groups based on pathological risk factors for recurrence. Patients in the low-risk pathology group will receive no adjuvant treatment, as in standard practice. Patients in the intermediate-risk pathology group will be randomised to receive either standard dose post-operative radiotherapy (control) or reduced dose radiotherapy. Patients in the high-risk pathology group will be randomised to receive either post-operative chemoradiotherapy (control) or radiotherapy alone. The primary outcome of the phase II study is patient reported swallowing function measured using the MD Anderson Dysphagia Inventory score at 12 months post-treatment. If the phase II study is successful, PATHOS will proceed to a phase III non-inferiority trial with overall survival as the primary endpoint. PATHOS is a prospective, randomised trial for Human papillomavirus-positive oropharyngeal cancer, which represents a different disease entity compared with other head and neck cancers. The trial aims to demonstrate that long-term dysphagia can be lessened by reducing the intensity of adjuvant treatment without having a negative impact on clinical outcome. The study will standardise transoral surgery and post-operative intensity-modulated radiotherapy protocols in the UK and develop a gold-standard swallowing assessment panel. An associated planned translational research programme, underpinned by tumour specimens and sequential blood collected as part of PATHOS, will facilitate further empirical understanding of this new disease and its response to treatment. This study is registered with ClinicalTrials.gov identifier NCT02215265 .

26 August 2016 in Cancer
Verified
Journal Article
Open access
PDF file
KHKatherine A. Hutcheson
Katherine A. Hutcheson
MBMartha P. Barrow
Martha P. Barrow
DBDenise A. Barringer
Denise A. Barringer
JKJodi K. Knott
Jodi K. Knott
HLHeather Y. Lin
Heather Y. Lin
JLJan S. Lewin
Jan S. Lewin
BACKGROUND: The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) is the universal framework for toxicity reporting in oncology trials. The objective of this study was to develop a CTCAE‐compatible modified barium swallow (MBS) grade for the purpose of grading pharyngeal dysphagia as a toxicity endpoint in cooperative‐group organ‐preservation trials for head and neck cancer (HNC). It was hypothesized that a 5‐point, CTCAE‐compatible MBS grade (Dynamic Imaging Grade of Swallowing Toxicity [DIGEST]) based on the interaction of pharyngeal residue and laryngeal penetration/aspiration ratings would be feasible and psychometrically sound.METHODS: A modified Delphi exercise was conducted for content validation, expert consensus, and operationalization of DIGEST criteria. Two blinded raters scored 100 MBSs conducted before or after surgical or nonsurgical organ preservation. Intrarater and interrater reliability was tested with weighted κ values. Criterion validity against oropharyngeal swallow efficiency (OPSE), the Modified Barium Swallow Impairment Profile (MBSImP™©), the MD Anderson Dysphagia Inventory (MDADI), and the Performance Status Scale for Head and Neck Cancer Patients (PSS‐HN) was assessed with a 1‐way analysis of variance and post hoc pairwise comparisons between DIGEST grades.RESULTS: Intrarater reliability was excellent (weighted κ = 0.82‐0.84) with substantial to almost perfect agreement between raters (weighted κ = 0.67‐0.81). DIGEST significantly discriminated levels of pharyngeal pathophysiology (MBSImP™©: r = 0.77; P < .0001), swallow efficiency (OPSE: r = –0.56; P < .0001), perceived dysphagia (MDADI: r = –0.41; P < .0001), and oral intake (PSS‐HN diet: r = –0.49; P < .0001).CONCLUSIONS: With the development of DIGEST, the MBS rating has been adapted to the CTCAE nomenclature of ordinal toxicity grading used in oncology trials. DIGEST offers a psychometrically sound measure for HNC clinical trials and investigations of toxicity profiles, dose responses, and predictive modeling. Cancer 2017;62–70. © 2016 American Cancer Society.

1 June 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
AGAaron J Grossberg
Aaron J Grossberg
SCSasikarn Chamchod
Sasikarn Chamchod
CFClifton David Fuller
Clifton David Fuller
Abdallah Sherif Radwan MohamedAbdallah Sherif Radwan Mohamed
Abdallah Sherif Radwan Mohamed
JHJolien Heukelom
Jolien Heukelom
DRDavid I. Rosenthal
David I. Rosenthal
Significant weight loss is common in patients with head and neck squamous cell carcinoma (HNSCC).1,2 In these patients, weight loss is complicated by tumor location and the subsequent local toxic effects of radiotherapy (RT) and chemoradiotherapy (CRT). Because these factors make food intake challenging, patients receiving RT or CRT are offered dietary counseling, nutritional supplementation, and often feeding tubes. However, multiple trials evaluating nutritional interventions have failed to show an improvement in survival.3 Weight loss is commonly used to screen the risk for poor outcomes in the clinical setting, but contradictory studies leave the relationship between treatment-associated weight loss and survival unclear.4-6